Rebecca Burdine is a faculty member in the Department of Molecular Biology at Princeton University. Her lab focuses on understanding the mechanisms that control left-right patterning and asymmetric organ morphogenesis. She was named the 44th Mallinckrodt Scholar for the Edward Mallinckrodt Jr. Foundation, and received a Scientist Development Career Award from the American Heart Association in 2003. She was elected as fellow to the American Association for the Advancement of Science (AAAS) in 2018. She is on the Editorial board for Cell Reports and Zebrafish, and regularly serves on grant review panels for the NIH and NSF.
Dr. Burdine is a parent to a child with Angelman Syndrome. She first served on the ASF scientific advisory committee in 2007 by invitation from Dr. Joe Wagstaff. She has previously served as Chief Scientific Officer for the Pitt-Hopkins Research Foundation and for the Foundation for Angelman Syndrome Therapeutics. She is currently serving on the steering committee for the Angelman Syndrome Natural History study and on the Clinical Trial Steering Committee for the STARS and NEPTUNE studies conducted by Ovid Therapeutics.